Lexicon Pharmaceuticals, Inc. (LXRX)
$
1.1
-0.05 (-4.55%)
Key metrics
Financial statements
Free cash flow per share
-0.2826
Market cap
399.7 Million
Price to sales ratio
6.8411
Debt to equity
0.4747
Current ratio
4.1648
Income quality
0.8448
Average inventory
184.5 Thousand
ROE
-0.8363
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Lexicon Pharmaceuticals, Inc. is dedicated to the discovery, development, and commercialization of pharmaceutical products, having achieved a revenue of $31,081,000.00 indicating its niche market focus. The cost of revenue for the company is $616,000.00 showcasing its production and operational expenses. The company’s stock is identified with the symbol 'LXRX' in the market, and its gross profit ratio stands at 0.98 reflecting the efficiency of the company's production and sales operations. Furthermore, the operating income ratio is -6.34 indicating the company's operational profitability margin. The company is engaged in the development of orally-delivered small molecule drug candidates, including Sotagliflozin, which has successfully completed Phase III clinical trials for the treatment of heart failure and type 1 diabetes, as well as LX9211, currently in Phase II clinical development for neuropathic pain management. Lexicon also maintains strategic collaborations and license agreements with Bristol-Myers Squibb Company and Genentech, Inc., enhancing its market presence. Founded in 1995, the company is headquartered in The Woodlands, Texas. In the investment landscape, the stock is affordable at $1.18 making it suitable for budget-conscious investors. Additionally, the stock exhibits a high average trading volume of 3,619,323.00 indicating strong liquidity. With a market capitalization of $399,738,900.00 the company is classified as a small-cap player within the biopharmaceutical sector. Lexicon Pharmaceuticals, Inc. is recognized as a key player in the Biotechnology industry, contributing significantly to the overall market landscape. It belongs to the Healthcare sector, driving innovation and growth within its field. Through its robust pipeline and strategic partnerships, Lexicon continues to strive toward enhancing healthcare outcomes while providing investors with potential opportunities for growth in a rapidly evolving market.
Is Lexicon Pharmaceuticals, Inc. (LXRX) a good investment?
Investing in Lexicon Pharmaceuticals, Inc. (LXRX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bearish outlook. Always conduct your own research before investing.
What is Lexicon Pharmaceuticals, Inc. (LXRX)'s stock forecast?
Analysts predict Lexicon Pharmaceuticals, Inc. stock to fluctuate between $0.28 (low) and $2.17 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Lexicon Pharmaceuticals, Inc.'s market capitalization?
As of 2025-08-29, Lexicon Pharmaceuticals, Inc.'s market cap is $399,738,900, based on 363,399,000 outstanding shares.
How does Lexicon Pharmaceuticals, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Lexicon Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Lexicon Pharmaceuticals, Inc. (LXRX) stock?
To buy Lexicon Pharmaceuticals, Inc. (LXRX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for LXRX. Place an order (Market, Limit, etc.).
What is the best time to invest in Lexicon Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Lexicon Pharmaceuticals, Inc. stock ever split?
Lexicon Pharmaceuticals, Inc.'s last stock split was 1:7 on 2015-05-21.
How did Lexicon Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $31,081,000 | EPS: -$0.63 | Growth: -21.25%.
Where can I find Lexicon Pharmaceuticals, Inc.'s investor relations reports?
Visit https://www.lexpharma.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Lexicon Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Lexicon Pharmaceuticals, Inc. stock?
All-time high: $6.33 (2021-10-15) | All-time low: $0.28 (2025-03-03).
What are the key trends affecting Lexicon Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
THE WOODLANDS, Texas, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at Citi's Biopharma Back to School Conference on Wednesday, September 3 at 1:45 p.m. ET and at the H.C.
seekingalpha.com
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants Craig B. Granowitz - Senior VP & Chief Medical Officer Lisa M.
zacks.com
Lexicon Pharmaceuticals (LXRX) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.08 per share. This compares to a loss of $0.17 per share a year ago.
globenewswire.com
Partnership discussions for pilavapadin remain underway following Phase 2b PROGRESS study results IND-enabling studies of LX9851 for obesity and related disorders on track for completion in 2025 with licensee Novo Nordisk expected to submit IND Enrollment completion for SONATA Phase 3 study in both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) on target for 2026 Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2025, and provided an update on key corporate milestones and accomplishments. “We continue to make great strides against the strategy we set forth as an R&D focused company,” said Mike Exton, Ph.D.
globenewswire.com
THE WOODLANDS, Texas, June 18, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from a study evaluating the impact of sotagliflozin on hypoglycemia in people with type 1 diabetes will be delivered as an oral presentation on Sunday, June 22, during the 85th Scientific Sessions of the American Diabetes Association (ADA). At the meeting, the company will also present topline data from its PROGRESS Phase 2b study evaluating pilavapadin (LX9211) in adults with diabetic peripheral neuropathic pain.
seekingalpha.com
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q1 2025 Earnings Conference Call May 13, 2025 5:00 PM ET Company Participants Lisa DeFrancesco - Senior Vice President, Investor Relations and Corporate Strategy Mike Exton - Chief Executive Officer and Director Scott Coiante - Senior Vice President and Chief Financial Officer Craig Granowitz - Senior Vice President and Chief Medical Officer Conference Call Participants Andrew Tsai - Jefferies Roanna Ruiz - Leerink Partners Yasmeen Rahimi - Piper Sandler Yigal Nochomovitz - Citigroup Lander Gorrono - H.C. Wainwright Operator Welcome to the Lexicon Pharmaceuticals First Quarter 2025 Financial Results Conference Call.
globenewswire.com
THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, taking place at the Nasdaq World Headquarters in New York City, on Tuesday, May 20, at 9:30 a.m. ET.
zacks.com
The upside comes after Lexicon lands a deal worth $1 billion for its experimental obesity drug with Novo Nordisk.
globenewswire.com
Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and near-term milestone payments Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and near-term milestone payments
seekingalpha.com
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q4 2024 Earnings Conference Call March 6, 2025 5:00 PM ET Company Participants Lisa DeFrancesco - Senior Vice President, Investor Relations and Corporate Strategy Mike Exton - Chief Executive Officer and Director Scott Coiante - Senior Vice President and Chief Financial Officer Craig Granowitz - Senior Vice President and Chief Medical Officer Conference Call Participants Joseph Stringer - Needham & Co. Joe Pantginis - H.C. Wainwright Andrew Tsai - Jefferies Operator Welcome to the Lexicon Pharmaceuticals Fourth Quarter 2024 Financial Results Conference Call.
See all news
